JNJ

229.12

+0.77%↑

ISRG

497.61

-1.2%↓

ABT

109.31

+0.07%↑

RDY

13.47

+0.52%↑

NEOG

10.43

+2.15%↑

JNJ

229.12

+0.77%↑

ISRG

497.61

-1.2%↓

ABT

109.31

+0.07%↑

RDY

13.47

+0.52%↑

NEOG

10.43

+2.15%↑

JNJ

229.12

+0.77%↑

ISRG

497.61

-1.2%↓

ABT

109.31

+0.07%↑

RDY

13.47

+0.52%↑

NEOG

10.43

+2.15%↑

JNJ

229.12

+0.77%↑

ISRG

497.61

-1.2%↓

ABT

109.31

+0.07%↑

RDY

13.47

+0.52%↑

NEOG

10.43

+2.15%↑

JNJ

229.12

+0.77%↑

ISRG

497.61

-1.2%↓

ABT

109.31

+0.07%↑

RDY

13.47

+0.52%↑

NEOG

10.43

+2.15%↑

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Abierto

SectorSanidad

8.29 2.09

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.04

Máximo

8.34

Métricas clave
By Trading Economics
Ingresos	-8M -74M
Ventas	5.5M 21M
Margen de beneficios	-357.186
Empleados	192
EBITDA	-1.3M -74M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+250.99% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-102M 746M
Apertura anterior	6.2
Cierre anterior	8.29

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

285 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 feb 2026, 23:59 UTC

Charlas de Mercado

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

1 feb 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

1 feb 2026, 23:44 UTC

Charlas de Mercado

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

1 feb 2026, 12:47 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

1 feb 2026, 03:02 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

1 feb 2026, 03:01 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium Currently Owns Near 20% Stake in STT GDC

1 feb 2026, 03:01 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

31 ene 2026, 18:48 UTC

Adquisiciones, fusiones, absorciones

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31 ene 2026, 16:40 UTC

Ganancias

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31 ene 2026, 09:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30 ene 2026, 23:41 UTC

Charlas de Mercado

Deckers Outdoor Seen as Undervalued -- Market Talk

30 ene 2026, 23:12 UTC

Adquisiciones, fusiones, absorciones

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30 ene 2026, 22:20 UTC

Ganancias

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30 ene 2026, 22:10 UTC

Charlas de Mercado

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30 ene 2026, 21:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

30 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

30 ene 2026, 21:42 UTC

Ganancias

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 ene 2026, 21:36 UTC

Ganancias

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30 ene 2026, 21:33 UTC

Ganancias

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30 ene 2026, 20:42 UTC

Ganancias

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 ene 2026, 20:37 UTC

Adquisiciones, fusiones, absorciones

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

250.99% repunte

Estimación a 12 Meses

Media 28.5 USD 250.99%

Máximo 40 USD

Mínimo 16 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

285 / 352 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.